Stock Market News
Scancell acquires novel antibodies from University of Nottingham
Novel immunotherapies developer Scancell Holdings has entered into an agreement with the University of Nottingham, it announced on Wednesday, to acquire a number of novel monoclonal antibodies to tumour-associated glycans.
The AIM-traded firm said alongside that, it also acquired a proprietary technology to enable the modification of the constant region of a human antibody to allow direct tumour killing.
Together, ita board said those offered a complementary platform to its existing cancer immunotherapy platforms, 'ImmunoBody' and 'Moditope'.
It explained that advances in understanding the pattern of sugars that adorn cells had highlighted important differences between those on tumour cells compared to their normal counterparts.
That altered sugar signature of tumour cells was said to be "intricately linked" to the majority of cancer cell biology hallmarks.
Antibodies that targeted such tumour glycan signatures, when coupled to a novel approach to invoke an immune response on binding, provided an attractive strategy for immunotherapy and formed the basis of the platform technology developed by professor Lindy Durrant and her team at the Nottingham University Therapeutic Antibody Centre, Scancell said.
Scancell would be responsible for the management, prosecution and maintenance of any patent applications assigned from the University of Nottingham to Scancell, as well as for the filing of new patent applications for the assigned antibodies.
Under the terms of the agreement, the University of Nottingham would be eligible to receive royalties on future licence revenue or net sales arising from the assigned antibodies.
"Professor Durrant and the team at NUTAC have developed a versatile method to generate high-affinity monoclonal antibodies against cancer cell glycans that, when coupled to a novel method of activating the immune system, have potential as a new class of cancer immunotherapy," said Scancell CEO Dr Cliff Holloway.
"We believe this platform complements our existing ImmunoBody and Moditope platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline."
Dr Susan Huxtable, director of technology transfer for the University of Nottingham, said the organisation had "great confidence" in Scancell's ability to further develop its intellectual property.
"The mutually-beneficial relationship between Scancell and the university is an excellent example of university technology transfer in action."
The AIM-traded firm said alongside that, it also acquired a proprietary technology to enable the modification of the constant region of a human antibody to allow direct tumour killing.
Together, ita board said those offered a complementary platform to its existing cancer immunotherapy platforms, 'ImmunoBody' and 'Moditope'.
It explained that advances in understanding the pattern of sugars that adorn cells had highlighted important differences between those on tumour cells compared to their normal counterparts.
That altered sugar signature of tumour cells was said to be "intricately linked" to the majority of cancer cell biology hallmarks.
Antibodies that targeted such tumour glycan signatures, when coupled to a novel approach to invoke an immune response on binding, provided an attractive strategy for immunotherapy and formed the basis of the platform technology developed by professor Lindy Durrant and her team at the Nottingham University Therapeutic Antibody Centre, Scancell said.
Scancell would be responsible for the management, prosecution and maintenance of any patent applications assigned from the University of Nottingham to Scancell, as well as for the filing of new patent applications for the assigned antibodies.
Under the terms of the agreement, the University of Nottingham would be eligible to receive royalties on future licence revenue or net sales arising from the assigned antibodies.
"Professor Durrant and the team at NUTAC have developed a versatile method to generate high-affinity monoclonal antibodies against cancer cell glycans that, when coupled to a novel method of activating the immune system, have potential as a new class of cancer immunotherapy," said Scancell CEO Dr Cliff Holloway.
"We believe this platform complements our existing ImmunoBody and Moditope platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline."
Dr Susan Huxtable, director of technology transfer for the University of Nottingham, said the organisation had "great confidence" in Scancell's ability to further develop its intellectual property.
"The mutually-beneficial relationship between Scancell and the university is an excellent example of university technology transfer in action."
Related share prices |
---|
Scancell Holdings (SCLP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price